Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV002273556 | SCV002558396 | uncertain significance | not provided | 2022-02-01 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function |
Genome Diagnostics Laboratory, |
RCV002277628 | SCV002565990 | uncertain significance | Ehlers-Danlos syndrome | 2020-12-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003101553 | SCV003255919 | uncertain significance | Ehlers-Danlos syndrome, dermatosparaxis type | 2022-07-08 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 244 of the ADAMTS2 protein (p.Gly244Asp). This variant is present in population databases (rs769174562, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with ADAMTS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |